Award recipients to present Distinguished Lectures
Award recipients Dr Richard Garrett and Dr Nigel Lengkeek with Dr Tien Pham will deliver a Distinguished Lecture on 15 November at ANSTO.
Showing 841 - 860 of 1016 results
Award recipients Dr Richard Garrett and Dr Nigel Lengkeek with Dr Tien Pham will deliver a Distinguished Lecture on 15 November at ANSTO.
Research has demonstrated that internally generated neutrons could be used to effectively target micro-infiltrates and cancer cells outside of the defined treatment regions.
Part of the Large Hardon Collider
Research and development activity explores new, boutique radioisotopes, including positron, gamma and beta/gamma emitter. The aim is to provide material for the next generation of diagnostic and therapeutic radiopharmaceuticals
This program explores the mechanism and outcome of the interaction of radiation on biological systems in order to improve our understanding of the impact of radiation on the brain, optimise radiotherapy and develop mitigation strategies for space travellers.
Shorebirds Competition 2022 results.
Dr Storr has worked for over 40 years in nuclear science and technology in a range of positions spanning operations, research and executive management.
Role at ANSTO
Dr Richard Mole is an instrument scientist co-responsible for the cold-neutron time-of-flight spectrometer PELICAN.
ANSTO is contributing to key critical minerals projects funded by the Federal Government.
A new systematic investigation of the origins of atomic structural distortions in compounds containing uranium has relevance for spent nuclear fuel .
ANSTO is one of the world's leading providers of irradiation services for silicon ingots, which are used by the multimillion dollar electronics industry across Europe and Asia. Each year, ANSTO irradiates more than 50 tonnes of silicon.
The use of radioisotopes, radiolabeled molecules and radioactive particles in conjunction with a range of quantitative imaging spectroscopy and radiation counting methods.
Innovative medical device Rhenium-SCT® therapy for non-melanoma skin cancer is now available in Australia
ANSTO’s OPAL multi-purpose research reactor at Lucas Heights has officially returned to power and recommenced operations, following a months-long planned shutdown to carry out essential maintenance and upgrades.